XTLB — XTL BIOPHARMACEUTICALS LTD
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1023549 ·
Last close
$2.38
Market Cap
$5.63M
52W High
$4.87
52W Low
$2.01
ADV30
36,284
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2024 | 289,000 | -43,000 | -812,000 | -255,000 | 8,550,000 | 371,000 | 3,115,000 |
| Sep 2024 | 162,000 | — | -764,000 | -553,000 | 9,280,000 | 820,000 | 3,563,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-159,009,000
Inventory
—
Receivables
$150,000
ST Investments
$772,000
EBIT TTM
$-939,000
Pretax Income TTM
$-938,000
Interest Exp TTM
$-1,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$968,000
EBITDA
—
Free Cash Flow
—
Enterprise Value
$4,894,965
Total Cash
$259,000
Total Debt
$86,000
Shares Out
2,365,608
Trailing EPS
$-3.60
Book Value
$0.00
ROE
-577.1%
ROA
-240.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2024 | 451,000 | -2,172,000 | -1,027,000 | 8,550,000 | 3,115,000 | — | -1,618,000 |
| Dec 2023 | 0 | -765,000 | -1,782,000 | 2,426,000 | 206,000 | — | -707,000 |
| Dec 2022 | 0 | -880,000 | -1,348,000 | 4,186,000 | 187,000 | — | -901,000 |
| Dec 2021 | 0 | -1,031,000 | 435,000 | 6,618,000 | 1,285,000 | — | -1,049,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| APVO | Aptevo Therapeutics Inc. | $5.66M | $4.54 | — |
| ADIL | ADIAL PHARMACEUTICALS, INC. | $5.56M | $2.54 | — |
| ENVB | Enveric Biosciences, Inc. | $5.52M | $1.37 | — |
| PCSA | Processa Pharmaceuticals, Inc. | $5.75M | $2.09 | — |
| TCRT | Alaunos Therapeutics, Inc. | $5.47M | $2.24 | — |
News headlines (Yahoo Finance, 1h cache)
XTL Announces Receipt of Staff Delist Determination from Nasdaq
2026-05-22 20:10 · Yahoo
XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologi
2026-04-29 12:58 · Yahoo
XTL Biopharmaceuticals Announces ADS Ratio Change
2026-03-20 20:10 · Yahoo
XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing
2026-02-27 21:30 · Yahoo
XTL Update on Recent Developments
2026-01-29 21:05 · Yahoo
XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency
2026-01-23 21:10 · Yahoo
Top Midday Gainers
2026-01-13 18:54 · Yahoo
XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
2026-01-13 14:28 · Yahoo
XTL Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
2026-01-13 12:30 · Yahoo
XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
2025-12-24 21:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.